KP
VRTX icon

Keel Point’s Vertex Pharmaceuticals VRTX Stock Holding History

Keel Point’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Buy
1,000
+53
+6% +$23.5K 0.03% 288
2026
Q1 		$423K Sell
947
-269
-22% -$125K 0.03% 292
2025
Q4 		$551K Buy
1,216
+85
+8% +$36.6K 0.03% 276
2025
Q3 		$443K Sell
1,131
-157
-12% -$65.6K 0.03% 325
2025
Q2 		$573K Buy
1,288
+104
+9% +$47.9K 0.04% 269
2025
Q1 		$574K Buy
1,184
+217
+22% +$101K 0.04% 221
2024
Q4 		$389K Sell
967
-442
-31% -$205K 0.03% 279
2024
Q3 		$655K Sell
1,409
-10
-0.7% -$4.8K 0.05% 191
2024
Q2 		$664K Buy
1,419
+397
+39% +$172K 0.06% 186
2024
Q1 		$427K Buy
1,022
+458
+81% +$194K 0.04% 228
2023
Q4 		$229K Buy
+564
New +$208K 0.03% 305

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Keel Point's VRTX Position: Q2 2026 in Review

Keel Point increased its Vertex Pharmaceuticals (VRTX) stake by 5.6% in Q2 2026, buying an estimated $23.5K and bringing the position to 1,000 shares worth $497K. The position accounts for 0.03% of the portfolio, ranked #288.

Keel Point first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $664K in Q2 2024. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Keel Point held 1,000 shares of Vertex Pharmaceuticals worth $497K as of Q2 2026.
  • Keel Point bought 53 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Vertex Pharmaceuticals made up 0.03% of Keel Point's portfolio in Q2 2026, its #288 holding.
  • Keel Point first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Keel Point's Vertex Pharmaceuticals position peaked at $664K in Q2 2024.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.